Pierre LaPalme
Vorsitzender bei GLyPharma Therapeutic, Inc.
Profil
Pierre Lapalme currently works at GLyPharma Therapeutic, Inc., as Chairman from 2012.
Mr. Lapalme also formerly worked at Rhone-Poulenc Rorer, Inc., as Chief Executive Officer & Executive Vice President, North America Ethypharm, Inc., as President & Chief Executive Officer from 1995 to 2003, Rhone-Poulenc Canada, Inc., as Chairman & Chief Executive Officer from 1979 to 1990, Rhone-Poulenc Pharmaceuticals, Inc., as Chairman & Chief Executive Officer in 1994, Shionogi Pharma, Inc., as Chairman from 2000 to 2008, Bioxel Pharma, Inc., as Chairman from 2002 to 2009, Pediapharm, Inc., as Chairman from 2013 to 2018, Medexus Pharmaceuticals, Inc., as Chairman from 2013 to 2018, BioMarin Pharmaceutical, Inc., as Director from 2015 to 2016, Æterna Zentaris, Inc., as Independent Director from 2012 to 2016, BioCapital Investment Advisors, Inc., as Director from 2003 to 2005, Confab, Inc., as Director, National Pharmaceutical Council, as Director, Algorithme Pharma, Inc., as Director, Canada's Research Based Pharmaceutical Cos., as Director, Pharmaceutical Manufacturers Association of Canada, as Director, INSYS Therapeutics, Inc., as Independent Director from 2011 to 2019, Sciele Pharmaceuticals, Inc., as Director from 2000 to 2008, Ciba-Geigy Corp., as Senior Vice President-Sales & Marketing, and Sanofi, as Senior Vice President & GM-North America Ethicals.
Aktive Positionen von Pierre LaPalme
| Unternehmen | Position | Beginn |
|---|---|---|
GLyPharma Therapeutic, Inc.
 GLyPharma Therapeutic, Inc. BiotechnologyHealth Technology GLyPharma Therapeutic, Inc. develops oncology therapeutic treatment. It engages in the development of the clinical efficacy of FE 203799, a novel proprietary Glucagon-Like Peptide-2(GLP-2) analogue exerting unique pharmacological effects in a first-in-class, meaningful indication for patients with hematological malignancies receiving myelotoxic therapies. The company was founded in August 2012 and is headquartered in Montreal, Canada. | Vorsitzender | 01.01.2012 |
Ehemalige bekannte Positionen von Pierre LaPalme
| Unternehmen | Position | Ende |
|---|---|---|
| INSYS THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 05.06.2019 |
| MEDEXUS PHARMACEUTICALS INC. | Vorsitzender | 19.12.2018 |
| Pediapharm, Inc. /Old/ | Vorsitzender | 01.12.2018 |
| BIOMARIN PHARMACEUTICAL INC. | Vorsitzender | 01.06.2015 |
| AETERNA ZENTARIS INC. | Direktor/Vorstandsmitglied | 01.01.2016 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| BIOMARIN PHARMACEUTICAL INC. | Health Technology |
| AETERNA ZENTARIS INC. | Health Technology |
| SANOFI | Health Technology |
| MEDEXUS PHARMACEUTICALS INC. | Health Technology |
| Private Unternehmen | 17 |
|---|---|
| Ciba-Geigy Corp. | Health Technology |
Shionogi Pharma, Inc.
 Shionogi Pharma, Inc. Pharmaceuticals: MajorHealth Technology Shionogi Pharma, Inc. manufactures pharmaceuticals. The company is headquartered in Alpharetta, GA. | Health Technology |
Bioxel Pharma, Inc.
 Bioxel Pharma, Inc. BiotechnologyHealth Technology Bioxel Pharma, Inc. develops pharmaceutical products used in the treatment of cancer, multiple sclerosis and Alzheimers. The company is engaged in the development, production and distribution of therapeutically active taxanes isolated from the Canadian yew. Bioxel Pharma was founded on July 13, 1995 and is headquartered in Quebec, Canada. | Health Technology |
BioCapital Investment Advisors, Inc.
 BioCapital Investment Advisors, Inc. Investment ManagersFinance Montréal-based BioCapital Investment Advisors, Inc. manages the BioCapital health technology mutual fund family. | Finance |
Rhone-Poulenc Rorer, Inc.
 Rhone-Poulenc Rorer, Inc. Pharmaceuticals: MajorHealth Technology Rhone-Poulenc Rorer, Inc. discovers, develops and markets human pharmaceuticals. It operates in all major markets of the world. The company is headquartered in Collegeville, PA. | Health Technology |
| Confab, Inc. | Consumer Non-Durables |
National Pharmaceutical Council
 National Pharmaceutical Council Miscellaneous Commercial ServicesCommercial Services The National Pharmaceutical Council operates as a not for profit organization. It specializes in research development, information dissemination, education, and communication of information to patients. The company was founded in 1953 and is headquartered in Washington, DC. | Commercial Services |
Algorithme Pharma, Inc.
 Algorithme Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Algorithme Pharma, Inc. engages in the provision of cal research services. The company was founded by Louis Caillé in 1992 and is headquartered in Laval, Canada. | Commercial Services |
| Canada's Research Based Pharmaceutical Cos. | |
| North America Ethypharm, Inc. | |
| Rhone-Poulenc Canada, Inc. | |
| Pharmaceutical Manufacturers Association of Canada | |
| Pediapharm, Inc. /Old/ | Health Technology |
INSYS Therapeutics, Inc.
 INSYS Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology INSYS Therapeutics, Inc. operates as a pharmaceutical company, which develops and commercializes supportive care products. It focuses on utilizing commercial pharmaceutical products that include Subsys, a proprietary sublingual fentanyl spray for BTCP in opioid-tolerant adult patients; and Syndros, a proprietary orally administered liquid formulation of dronabinol for the treatment of CINV and anorexia associated with weight loss in patients with AIDS. The company was founded by John N. Kapoor on June 15, 1990 and is headquartered in Chandler, AZ. | Health Technology |
| Rhone-Poulenc Pharmaceuticals, Inc. | |
GLyPharma Therapeutic, Inc.
GLyPharma Therapeutic, Inc. BiotechnologyHealth Technology GLyPharma Therapeutic, Inc. develops oncology therapeutic treatment. It engages in the development of the clinical efficacy of FE 203799, a novel proprietary Glucagon-Like Peptide-2(GLP-2) analogue exerting unique pharmacological effects in a first-in-class, meaningful indication for patients with hematological malignancies receiving myelotoxic therapies. The company was founded in August 2012 and is headquartered in Montreal, Canada. | Health Technology |
| Sciele Pharmaceuticals, Inc. |
